Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarker... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Evaluating the efficacy and safety of Platelet Rich Plasma for patients with Peyronie’s disease: ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'SURFactant Administration by SUPraglottic Airway (the SURFSUP Trial)'. The following are the othe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpa... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemothe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy,and Pharmacokinetics o... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Part... Read More